CNTB · Connect Biopharma Holdings Ltd
$2.14
-0.06 (-2.73%)
At close · Jul 24
Market Cap
$134.74M
Shares
62.96M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$64K
-99.8%
FY2025
Net Income
-$55.48M
-255%
FY2025
Operating Margin
-90740.62%
-90654.4pp
FY2025
Diluted EPS
-$1.00
-257.1%
FY2025
Operating Cash Flow
-$51.21M
-116.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $233K | $64K | $26.03M | $0 | |
| $46.2M | $37.8M | $29.26M | $53M | |
| $20.27M | $20.34M | $19.23M | $16.05M | |
| — | $704K | $660K | $720K | |
| — | — | $3.2M | — | |
| $66.47M | $58.14M | $48.49M | $69.06M | |
| -$66.23M | -$58.07M | -$22.45M | -$69.06M | |
| — | -90740.62% | -86.24% | — | |
| — | -$57.37M | -$21.79M | -$68.34M | |
| $1.82M | $2.79M | $7.05M | $7.07M | |
| -$64.42M | -$55.28M | -$15.41M | -$61.99M | |
| $191K | $197K | $223K | $120K | |
| -$64.61M | -$55.48M | -$15.63M | -$62.11M | |
| — | -86687.5% | -60.03% | — | |
| -$64.06M | -$55.01M | -$16.29M | -$62.37M | |
| USD/shares | — | -$1.00 | -$0.28 | -$1.13 |
| USD/shares | — | -$1.00 | -$0.28 | -$1.13 |
| shares | — | 55.66M | 55.21M | 55.07M |
| shares | — | 55.66M | 55.21M | 55.07M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Treatment of Respiratory Diseases Segment | $64,000 | $26,033,000 | $0 |